Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.

Revenue
+38.3%
EPS
−294.7%
Free cash flow
+5.09%
Total debt
+40.8%

Quarter to June 2026, against a year earlier

25.59 1.53 +6.36%
Market cap
$5.6B
P/E
0.0×
Fwd P/E
−49.4×
Dividend yield
—
F-score
4/9
Altman Z
4.10
Beneish M
n/a
Dividend safety
n/a

Hims & Hers Health, Inc. 10-K filed Feb 23, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 5:20 PM ET · Document on sec.gov · Filing index

What changed

Item 1A, Risk Factors, against the 10-K filed Feb 24, 2025: 62 added · 12 removed · 150 modified; 1 moved without change